SUPPLEMENTARY TABLE 1:

No of patients with GDM	Treatment modality in the pre-pregnancy BMI defined subgroup	MTNR1Brs10830963 genotype distribution in GDM patients with pre-pregnancy BMI < 27 kg/m²			Risk (G) allele frequency
122	All	*CC*	*CG*	*GG*	-
11	AIT	2	8	1	0.45
111	Non-pharmacological treatment only	45	51	15	0.36
No of patients with GDM	Treatment modality in the pre-pregnancy BMI defined subgroup	MTNR1Brs10830963 genotype distribution in GDM patients with pre-pregnancy BMI ≥ 27 kg/m2			Risk (G) allele frequency
89	All	*CC*	*CG*	*GG*	-
20	AIT	6	9	5	0.48
69	Non-pharmacological treatment only	35	28	6	0.29
No of patients with GDM	Treatment modality in the pre-pregnancy BMI defined subgroup	MTNR1Brs10830963 genotype distribution in GDM patients with pre-pregnancy BMI < 29 kg/m²			Risk (G) allele frequency
148	All	*CC*	*CG*	*GG*	-
15	AIT	5	8	2	0.40
133	Non-pharmacological treatment only	55	60	18	0.36
No of patients with GDM	Treatment modality in the pre-pregnancy BMI defined subgroup	MTNR1Brs10830963 genotype distribution in GDM patients with pre-pregnancy BMI ≥ 29 kg/m²			Risk (G) allele frequency
63	All	*CC*	*CG*	*GG*	-
16	AIT	3	9	4	0.53
47	Non-pharmacological treatment only	25	19	3	0.26

The *MTNR1B* rs10830963 genotype distributions and the number of GDM subjects in the AIT / non-AIT treatment modality subgroups according to the pre-pregnancy BMI cutoffs of 27 kg/m² and 29 kg/m².
Genotypes with the *risk allele G* are outlined in red colour.